CN103189056A - L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗 - Google Patents

L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗 Download PDF

Info

Publication number
CN103189056A
CN103189056A CN2011800412824A CN201180041282A CN103189056A CN 103189056 A CN103189056 A CN 103189056A CN 2011800412824 A CN2011800412824 A CN 2011800412824A CN 201180041282 A CN201180041282 A CN 201180041282A CN 103189056 A CN103189056 A CN 103189056A
Authority
CN
China
Prior art keywords
dopamine
dopa
agents
treatment
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800412824A
Other languages
English (en)
Chinese (zh)
Inventor
帕特里克·亚历山大·豪森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytopharm Ltd
Original Assignee
Phytopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Ltd filed Critical Phytopharm Ltd
Publication of CN103189056A publication Critical patent/CN103189056A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2011800412824A 2010-07-20 2011-07-20 L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗 Pending CN103189056A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36601510P 2010-07-20 2010-07-20
US61/366,015 2010-07-20
PCT/GB2011/051376 WO2012010896A1 (en) 2010-07-20 2011-07-20 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders

Publications (1)

Publication Number Publication Date
CN103189056A true CN103189056A (zh) 2013-07-03

Family

ID=44583771

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800412824A Pending CN103189056A (zh) 2010-07-20 2011-07-20 L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗

Country Status (13)

Country Link
US (1) US20130210786A1 (enExample)
EP (1) EP2595621A1 (enExample)
JP (1) JP2013543482A (enExample)
KR (1) KR20130043197A (enExample)
CN (1) CN103189056A (enExample)
AU (1) AU2011281336B2 (enExample)
BR (1) BR112013001422A2 (enExample)
CA (1) CA2805693A1 (enExample)
EA (1) EA201390070A1 (enExample)
MX (1) MX2013000760A (enExample)
SG (1) SG187090A1 (enExample)
WO (1) WO2012010896A1 (enExample)
ZA (1) ZA201301231B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115282156A (zh) * 2022-09-05 2022-11-04 广东海洋大学 知母皂苷元在制备防治帕金森病的药物中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
JP2017008044A (ja) * 2015-06-22 2017-01-12 学校法人 久留米大学 ドーパミンシグナル伝達の抑制剤
CN105106230A (zh) * 2015-08-16 2015-12-02 南京华宽信息咨询中心 一种单胺氧化酶mao抑制剂及其应用
AU2020323820B2 (en) * 2019-07-29 2024-07-18 Peptron, Inc. Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof
JP2022550569A (ja) 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4088721B1 (en) * 2020-01-08 2025-09-17 Neuroventi Composition for treating fragile x syndrome or related developmental disorders, comprising lisuride compound as active ingredient
JP2023537675A (ja) * 2020-08-17 2023-09-05 パイク セラピューティクス インコーポレイテッド パーキンソン病の治療のための医薬組成物及びその治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1642558A (zh) * 2002-03-27 2005-07-20 菲特法姆股份有限公司 皂角苷配基及其衍生物的治疗方法和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA985172A (en) 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
EP0102416A1 (en) 1982-08-23 1984-03-14 Nutrisearch Company Blends of egg albumen and whey protein of improved gel strength
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5371092A (en) * 1990-11-24 1994-12-06 Beecham Group, P.L.C. Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
AU749638B2 (en) 1997-03-17 2002-06-27 Btg International Limited Therapeutic compositions
CN1131237C (zh) 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9905275D0 (en) 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
TR200002774T2 (tr) * 1998-03-26 2001-06-21 Phytopharm Plc Alzheimer hastalığının tedavisi için steroit sapogenler ve bunların türevleri
CA2339941A1 (en) 1998-09-15 2000-03-23 Btg International Limited Use of cyclic esters of r-3-hydroxybutyrate for treatment of metabolic and neural degenerative disorders
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
EP1490071B1 (en) * 2002-03-27 2009-03-04 Phytopharm Plc Therapeutic uses of sapogenins
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
US20070041924A1 (en) * 2005-08-19 2007-02-22 Bioderm Research Sebum Control Compositions Based on Saponins and Sapogenins
AU2010207597A1 (en) * 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1642558A (zh) * 2002-03-27 2005-07-20 菲特法姆股份有限公司 皂角苷配基及其衍生物的治疗方法和用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M. ANGELA CENCI: "L-DOPA-induced dyskinesia:cellular mechanisms and approaches to treatment", 《PARKINSONISM & RELATED DISORDERS》, no. 13, 1 January 2007 (2007-01-01), pages 263 - 267 *
包•照日格图等: "三种甾体皂苷对心肌细胞M受体的影响", 《中国药理学通报》, vol. 21, no. 9, 30 September 2005 (2005-09-30), pages 1140 - 1142 *
张克义等主编: "《临床药物不良反应大典》", 30 September 2001, 辽宁科学技术出版社, article "左旋多巴", pages: 41-42 *
张振涛等: "左旋多巴诱导运动障碍的发病机制与防治", 《神经损伤与功能重建》, vol. 1, no. 4, 30 November 2006 (2006-11-30), pages 225 - 227 *
戴忠: "甾体皂苷研究进展", 《中国药师》, vol. 6, no. 10, 31 December 2003 (2003-12-31), pages 615 - 616 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115282156A (zh) * 2022-09-05 2022-11-04 广东海洋大学 知母皂苷元在制备防治帕金森病的药物中的应用

Also Published As

Publication number Publication date
JP2013543482A (ja) 2013-12-05
EA201390070A1 (ru) 2013-09-30
BR112013001422A2 (pt) 2019-09-24
ZA201301231B (en) 2014-04-30
EP2595621A1 (en) 2013-05-29
AU2011281336A1 (en) 2013-01-31
MX2013000760A (es) 2013-10-28
CA2805693A1 (en) 2012-01-26
US20130210786A1 (en) 2013-08-15
AU2011281336B2 (en) 2015-03-05
WO2012010896A1 (en) 2012-01-26
KR20130043197A (ko) 2013-04-29
SG187090A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
AU2011281336B2 (en) Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders
JP7210459B2 (ja) 老化防止剤及び老化防止方法
US8716249B2 (en) Compositions and methods for improving cardiovascular health
US20120034193A1 (en) Treatment of neurotrophic factor mediated disorders
US20220031596A1 (en) Anti-aging agent and anti-aging method
CN103800310A (zh) 以5-氨基乙酰丙酸或其衍生物、或它们的盐作为有效成分的成人病的预防、改善剂
JP2005513107A (ja) （−）−ヒドロキシクエン酸、クロム、およびギムネマ酸を含有する組成物、および健常体重を促進する方法と関連する健康因子を改善する方法
JP2019031504A (ja) トコトリエノールの経粘膜送達
BR112013028104A2 (pt) composição e método para tratamento de diabetes
JP4355967B2 (ja) 医薬組成物
CN101237862B (zh) 包含一氧化氮供体和二硫戊环的组合物及其在制备性功能改善的药物中的用途
KR20050084052A (ko) 남성 갱년기에 의해 유발되는 질환의 예방 및/또는 치료를위한 카르니틴의 용도
WO2007069744A1 (ja) メタボリックシンドローム予防・改善用組成物
US12458677B2 (en) Method for preparing Gynostemma pentaphyllum leaf extract and Gynostemma pentaphyllum leaf extract prepared thereby
JP5452042B2 (ja) 医薬組成物
JP2009539941A (ja) Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
JPWO2020080398A1 (ja) アルコール飲料摂取による悪酔い又は二日酔いの抑制剤
HK1166698A (en) Treatment of neurotrophic factor mediated disorders
KR20070022220A (ko) 오스페미펜의 생물학적 이용가능성 강화방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20160511

C20 Patent right or utility model deemed to be abandoned or is abandoned